Key Points
- Insider sale: Joana Goncalves sold 7,947 Oruka Therapeutics shares for approximately $734,144 under a pre-arranged Rule 10b5-1 plan to cover tax obligations. She retains 31,771 shares.
- Stock and earnings: ORKA opened at $92.20, with a market capitalization of about $6.1 billion. The company reported a quarterly loss of $0.55 per share, missing the $0.51 consensus estimate.
- Analyst outlook: Oruka has a consensus “Moderate Buy” rating from analysts, with an average price target of $133 versus the reported share price near $92.20, although one firm downgraded the stock to “sell.”
Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) SVP Arjun Agarwal sold 560 shares of the company's stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $95.71, for a total transaction of $53,597.60. Following the transaction, the senior vice president owned 14,752 shares in the company, valued at approximately $1,411,913.92. The trade was a 3.66% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Arjun Agarwal also recently made the following trade(s):
- On Friday, September 11th, Arjun Agarwal sold 9,459 shares of Oruka Therapeutics stock. The shares were sold at an average price of $92.23, for a total transaction of $872,403.57.
- On Thursday, August 13th, Arjun Agarwal sold 10,000 shares of Oruka Therapeutics stock. The shares were sold at an average price of $106.66, for a total transaction of $1,066,600.00.
- On Monday, July 13th, Arjun Agarwal sold 9,999 shares of Oruka Therapeutics stock. The shares were sold at an average price of $84.63, for a total transaction of $846,215.37.
- On Monday, June 22nd, Arjun Agarwal sold 1,587 shares of Oruka Therapeutics stock. The shares were sold at an average price of $80.95, for a total value of $128,467.65.
Oruka Therapeutics Stock Performance
Shares of ORKA opened at $92.20 on Wednesday. The firm has a market capitalization of $6.10 billion, a P/E ratio of -45.42 and a beta of -0.34. Oruka Therapeutics, Inc. has a 52 week low of $14.66 and a 52 week high of $115.51. The stock has a 50 day moving average price of $95.87 and a two-hundred day moving average price of $72.78.
Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last posted its earnings results on Monday, August 10th. The company reported ($0.55) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.04). On average, equities analysts forecast that Oruka Therapeutics, Inc. will post -2.42 earnings per share for the current year.
Trending Headlines about Oruka Therapeutics
Here are the key news stories impacting Oruka Therapeutics this week:
- Positive Sentiment: Analysts remain broadly optimistic about Oruka’s pipeline. Ten analysts rate the stock a Buy, compared with one Sell rating, and the consensus price target is $133, well above the recent trading range. BTIG, Wedbush, Mizuho and HC Wainwright have maintained favorable ratings or price targets ranging from $120 to $165. Oruka analyst ratings and price targets
- Positive Sentiment: The EVERLAST-A 28-plus-week data for ORKA-001 in psoriasis is being highlighted as a key upcoming catalyst. Positive durability or efficacy results could strengthen the investment case for Oruka’s long-acting antibody platform. EVERLAST-A data catalyst article
- Neutral Sentiment: Recent insider sales were conducted under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested equity awards. CEO Lawrence Klein sold 2,452 shares, SVP Arjun Agarwal sold 10,019 shares across two transactions, and Joana Goncalves sold 7,947 shares. Because the transactions were tax-related and planned in advance, they are less informative than discretionary sales, although they may still attract investor attention. Oruka insider sales report
- Negative Sentiment: Oruka remains an unprofitable clinical-stage biotechnology company. Its latest quarterly loss of $0.55 per share exceeded the expected $0.51 loss, and analysts expect a full-year loss of approximately $2.42 per share. The stock is also trading below its 50-day moving average, underscoring sensitivity to clinical updates and financing concerns.
Analyst Upgrades and Downgrades
ORKA has been the topic of several recent analyst reports. HC Wainwright restated a "buy" rating and set a $120.00 price objective on shares of Oruka Therapeutics in a research note on Thursday, September 3rd. Weiss Ratings upgraded shares of Oruka Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a report on Wednesday, July 15th. Mizuho set a $120.00 price target on shares of Oruka Therapeutics in a research report on Thursday, September 3rd. Wedbush reaffirmed an "outperform" rating and issued a $165.00 price objective on shares of Oruka Therapeutics in a research report on Tuesday, August 11th. Finally, Piper Sandler reiterated an "overweight" rating and issued a $180.00 price objective on shares of Oruka Therapeutics in a research note on Tuesday, June 2nd. Ten investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $133.00.
View Our Latest Stock Analysis on ORKA
Institutional Investors Weigh In On Oruka Therapeutics
A number of hedge funds have recently made changes to their positions in the business. Nykredit A S purchased a new position in shares of Oruka Therapeutics in the 2nd quarter worth about $29,000. Caitong International Asset Management Co. Ltd purchased a new stake in Oruka Therapeutics during the fourth quarter worth about $67,000. Orion Capital Management LLC bought a new stake in Oruka Therapeutics in the second quarter worth about $91,000. Royal Bank of Canada raised its position in Oruka Therapeutics by 178.5% in the first quarter. Royal Bank of Canada now owns 3,172 shares of the company's stock worth $155,000 after acquiring an additional 2,033 shares during the period. Finally, PNC Financial Services Group Inc. boosted its stake in Oruka Therapeutics by 119.7% in the first quarter. PNC Financial Services Group Inc. now owns 3,186 shares of the company's stock valued at $156,000 after acquiring an additional 1,736 shares during the last quarter. 56.44% of the stock is currently owned by institutional investors.
About Oruka Therapeutics
(
Get Free Report)
Oruka Therapeutics, Inc (NASDAQ:ORKA) is a clinical-stage biotechnology company developing long-acting monoclonal antibody therapies for immune-mediated diseases. The company's research is focused on creating medicines that may allow less frequent dosing than existing biologic treatments.
Oruka's initial development programs are aimed at inflammatory conditions, including psoriasis. Its pipeline includes engineered antibody candidates designed to target important immune pathways, including interleukin-23 and interleukin-17.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
